Logo image of USNA

USANA HEALTH SCIENCES INC (USNA) Stock Fundamental Analysis

NYSE:USNA - New York Stock Exchange, Inc. - US90328M1071 - Common Stock - Currency: USD

31.12  +0.17 (+0.55%)

After market: 31.12 0 (0%)

Fundamental Rating

6

Overall USNA gets a fundamental rating of 6 out of 10. We evaluated USNA against 35 industry peers in the Personal Care Products industry. While USNA has a great health rating, its profitability is only average at the moment. USNA has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

In the past year USNA was profitable.
USNA had a positive operating cash flow in the past year.
USNA had positive earnings in each of the past 5 years.
USNA had a positive operating cash flow in each of the past 5 years.
USNA Yearly Net Income VS EBIT VS OCF VS FCFUSNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

USNA has a Return On Assets of 4.64%. This is in the better half of the industry: USNA outperforms 62.86% of its industry peers.
USNA's Return On Equity of 6.42% is fine compared to the rest of the industry. USNA outperforms 71.43% of its industry peers.
The Return On Invested Capital of USNA (5.38%) is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for USNA is below the industry average of 13.76%.
The last Return On Invested Capital (5.38%) for USNA is well below the 3 year average (10.32%), which needs to be investigated, but indicates that USNA had better years and this may not be a problem.
Industry RankSector Rank
ROA 4.64%
ROE 6.42%
ROIC 5.38%
ROA(3y)9.11%
ROA(5y)13.39%
ROE(3y)12.23%
ROE(5y)18.88%
ROIC(3y)10.32%
ROIC(5y)15.36%
USNA Yearly ROA, ROE, ROICUSNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

USNA has a Profit Margin of 3.79%. This is in the better half of the industry: USNA outperforms 65.71% of its industry peers.
In the last couple of years the Profit Margin of USNA has declined.
Looking at the Operating Margin, with a value of 6.25%, USNA is in line with its industry, outperforming 60.00% of the companies in the same industry.
In the last couple of years the Operating Margin of USNA has declined.
With an excellent Gross Margin value of 79.93%, USNA belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
In the last couple of years the Gross Margin of USNA has remained more or less at the same level.
Industry RankSector Rank
OM 6.25%
PM (TTM) 3.79%
GM 79.93%
OM growth 3Y-18.51%
OM growth 5Y-10.85%
PM growth 3Y-20.58%
PM growth 5Y-12.29%
GM growth 3Y-0.21%
GM growth 5Y-0.29%
USNA Yearly Profit, Operating, Gross MarginsUSNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

8

2. Health

2.1 Basic Checks

USNA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, USNA has less shares outstanding
Compared to 5 years ago, USNA has less shares outstanding
Compared to 1 year ago, USNA has a worse debt to assets ratio.
USNA Yearly Shares OutstandingUSNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
USNA Yearly Total Debt VS Total AssetsUSNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 4.31 indicates that USNA is not in any danger for bankruptcy at the moment.
USNA has a better Altman-Z score (4.31) than 65.71% of its industry peers.
There is no outstanding debt for USNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.31
ROIC/WACC0.61
WACC8.77%
USNA Yearly LT Debt VS Equity VS FCFUSNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 2.15 indicates that USNA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.15, USNA is in line with its industry, outperforming 57.14% of the companies in the same industry.
A Quick Ratio of 1.47 indicates that USNA should not have too much problems paying its short term obligations.
USNA has a better Quick ratio (1.47) than 62.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.47
USNA Yearly Current Assets VS Current LiabilitesUSNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

4

3. Growth

3.1 Past

The earnings per share for USNA have decreased by -6.64% in the last year.
USNA shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.07% yearly.
USNA shows a small growth in Revenue. In the last year, the Revenue has grown by 2.75%.
Measured over the past years, USNA shows a decrease in Revenue. The Revenue has been decreasing by -4.23% on average per year.
EPS 1Y (TTM)-6.64%
EPS 3Y-23.07%
EPS 5Y-10.07%
EPS Q2Q%37.04%
Revenue 1Y (TTM)2.75%
Revenue growth 3Y-10.36%
Revenue growth 5Y-4.23%
Sales Q2Q%10.87%

3.2 Future

Based on estimates for the next years, USNA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.32% on average per year.
The Revenue is expected to grow by 9.38% on average over the next years. This is quite good.
EPS Next Y2.39%
EPS Next 2Y15.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.33%
Revenue Next 2Y9.38%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
USNA Yearly Revenue VS EstimatesUSNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
USNA Yearly EPS VS EstimatesUSNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 11.66, the valuation of USNA can be described as very reasonable.
USNA's Price/Earnings ratio is rather cheap when compared to the industry. USNA is cheaper than 91.43% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.84. USNA is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 9.00, which indicates a very decent valuation of USNA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of USNA indicates a rather cheap valuation: USNA is cheaper than 91.43% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.94. USNA is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.66
Fwd PE 9
USNA Price Earnings VS Forward Price EarningsUSNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, USNA is valued cheaper than 94.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 4.65
USNA Per share dataUSNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates USNA does not grow enough to justify the current Price/Earnings ratio.
USNA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as USNA's earnings are expected to grow with 15.32% in the coming years.
PEG (NY)4.87
PEG (5Y)N/A
EPS Next 2Y15.32%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for USNA!.
Industry RankSector Rank
Dividend Yield N/A

USANA HEALTH SCIENCES INC

NYSE:USNA (8/20/2025, 8:04:00 PM)

After market: 31.12 0 (0%)

31.12

+0.17 (+0.55%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)07-22 2025-07-22/amc
Earnings (Next)10-20 2025-10-20/amc
Inst Owners58.05%
Inst Owner Change2.83%
Ins Owners0.61%
Ins Owner Change-0.15%
Market Cap579.45M
Analysts43.33
Price Target62.22 (99.94%)
Short Float %6.83%
Short Ratio5.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.3%
Min EPS beat(2)2.24%
Max EPS beat(2)34.35%
EPS beat(4)4
Avg EPS beat(4)19.49%
Min EPS beat(4)2.24%
Max EPS beat(4)34.35%
EPS beat(8)6
Avg EPS beat(8)17.25%
EPS beat(12)9
Avg EPS beat(12)21.2%
EPS beat(16)10
Avg EPS beat(16)13.82%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.66%
Max Revenue beat(2)2.74%
Revenue beat(4)3
Avg Revenue beat(4)-0.23%
Min Revenue beat(4)-4.61%
Max Revenue beat(4)2.74%
Revenue beat(8)4
Avg Revenue beat(8)-1.39%
Revenue beat(12)7
Avg Revenue beat(12)-0.44%
Revenue beat(16)9
Avg Revenue beat(16)-0.74%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-27.69%
EPS NQ rev (3m)-24.8%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.75%
Revenue NQ rev (3m)-2.98%
Revenue NY rev (1m)0.79%
Revenue NY rev (3m)0.79%
Valuation
Industry RankSector Rank
PE 11.66
Fwd PE 9
P/S 0.64
P/FCF N/A
P/OCF 9.19
P/B 1.09
P/tB 2.37
EV/EBITDA 4.65
EPS(TTM)2.67
EY8.58%
EPS(NY)3.46
Fwd EY11.11%
FCF(TTM)-8.18
FCFYN/A
OCF(TTM)3.38
OCFY10.88%
SpS48.29
BVpS28.52
TBVpS13.11
PEG (NY)4.87
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.64%
ROE 6.42%
ROCE 9.17%
ROIC 5.38%
ROICexc 7.14%
ROICexgc 18.89%
OM 6.25%
PM (TTM) 3.79%
GM 79.93%
FCFM N/A
ROA(3y)9.11%
ROA(5y)13.39%
ROE(3y)12.23%
ROE(5y)18.88%
ROIC(3y)10.32%
ROIC(5y)15.36%
ROICexc(3y)25.77%
ROICexc(5y)39.61%
ROICexgc(3y)41.63%
ROICexgc(5y)58.84%
ROCE(3y)17.59%
ROCE(5y)26.19%
ROICexcg growth 3Y-27.3%
ROICexcg growth 5Y-19.15%
ROICexc growth 3Y-45.52%
ROICexc growth 5Y-31.11%
OM growth 3Y-18.51%
OM growth 5Y-10.85%
PM growth 3Y-20.58%
PM growth 5Y-12.29%
GM growth 3Y-0.21%
GM growth 5Y-0.29%
F-Score5
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 613.46%
Cap/Sales 23.95%
Interest Coverage 84.38
Cash Conversion 69.02%
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.47
Altman-Z 4.31
F-Score5
WACC8.77%
ROIC/WACC0.61
Cap/Depr(3y)385.75%
Cap/Depr(5y)273.18%
Cap/Sales(3y)9.41%
Cap/Sales(5y)6.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.64%
EPS 3Y-23.07%
EPS 5Y-10.07%
EPS Q2Q%37.04%
EPS Next Y2.39%
EPS Next 2Y15.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.75%
Revenue growth 3Y-10.36%
Revenue growth 5Y-4.23%
Sales Q2Q%10.87%
Revenue Next Year12.33%
Revenue Next 2Y9.38%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.36%
EBIT growth 3Y-26.96%
EBIT growth 5Y-14.62%
EBIT Next Year52.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-291.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.5%
OCF growth 3Y-20.46%
OCF growth 5Y-13.6%